These findings were particularly intriguing in light of our analysis of data from The Cancer Genome Atlas (TCGA), which revealed that FOXC2 expression levels correlate negatively with survival of melanoma patients treated with either dacarbazine chemotherapy or ipilimumab immunotherapy. This evidence concerns the gene FOXC2 and melanoma.